Promoting Biomedical Innovation and Economic Value: New Models for Reimbursement and Evidence Development
A central goal of health care reform is to provide more effective, personalized care at a lower cost. Medical breakthroughs enabled by modern science are key to achieving this goal. To ensure that Americans continue to benefit from these breakthroughs, we must take steps now to foster a culture of biomedical innovation. Simultaneously, to ensure that these breakthroughs are accessible and affordable for all who need them, we need to adopt policies that promote economic value in the delivery of health care.
On April 22, the Engelberg Center for Health Care Reform and the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California hosted an event with key stakeholders to discuss practical steps in reimbursement and evidence development that can promote such innovation and economic value. Former House Speaker Newt Gingrich and former Office of Management and Budget Director Peter Orszag offered keynote remarks.
Agenda
Welcome
Dana Goldman
Nonresident Senior Fellow - Economic Studies, USC-Brookings Schaeffer Initiative for Health Policy
Mark B. McClellan
Former Brookings Expert
Director, Margolis Center for Health Policy - Duke University
Opening Keynote Address
Newt Gingrich
Center for Health Transformation
Speaker of the House of Representatives during the welfare reform debate
Panel I: Impact of Different Reimbursement Systems on Innovation
Dana Goldman
Nonresident Senior Fellow - Economic Studies, USC-Brookings Schaeffer Initiative for Health Policy
Jerry Avorn
Harvard Medical School
Freda Lewis-Hall
Pfizer
Robert Epstein
Medco Health Solutions, Inc.
Panel II: Opportunities to Drive Innovation with New Payment Policies
Dana Goldman
Nonresident Senior Fellow - Economic Studies, USC-Brookings Schaeffer Initiative for Health Policy
Moderator: Reed Tuckson
UnitedHealth Group
Herve Hoppenot
Novartis Oncology
Norma Holtz
Health Alliance Medical Plans, Inc.
Steve Shak
Genomic Health
Panel III: Issues in Measuring Innovation and Value
Mark B. McClellan
Former Brookings Expert
Director, Margolis Center for Health Policy - Duke University
Uday N. Kumar
iRhythm Technologies, Inc.
Vicki L. Seyfert-Margolis
U.S. Food and Drug Administration
Lou Garrison
University of Washington
Closing Keynote Address
Peter R. Orszag
Vice Chairman of Investment Banking, Managing Director, and Global Co-Head of Healthcare - Lazard
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.
